Who decides the “value” of a new cancer drug — and how?

In an interesting wrinkle that may profoundly impact the drug pricing debate here in America, the American Society for Clinical Oncology (ASCO) has decided to “score” the value of new cancer drugs as they are brought to market. … READ MORE …

Who gets to “value” new drugs (at least in the UK)?

According to recent news reports (such as this one), the UK’s National Institute for Health and Clinical Excellence (NICE) will have full responsibility for determining the “value” of all drug therapies when a new drug pricing system is implemented in the UK in 2014. … READ MORE …

Sequencing of treatment with new therapeutic agents for advanced prostate cancer

The January 2012 issue of Oncology contains an open access, full-text article on the future sequencing of the recently approved and potentially new drugs that are or should soon be available for the treatment of advanced prostate cancer. … READ MORE …

Andy Pollack on new prostate cancer treatments in the New York Times

Many prostate cancer patients and advocates will want to read yesterday’s article by New York Times correspondent Andrew Pollack entitled, “New drugs fight prostate cancer, but at high cost.” The article offers a commentary on recent advances in the treatment of advanced prostate cancer — and the economic consequences.

What’s in the future pipeline for treatment of mCRPC?

Over the past year we have provided readers with extensive information about some of the new forms of therapy such as abiraterone acetate, MDV3100, TAK-700, and others that have shown great promise and are already in Phase III clinical trials for post-chemotherapy and chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …